Share
 
Title
Code
Session Type
Channel
Date Time
Co-Chairs:
Organizer:

The HIV epidemic, entering its fourth decade, has affected 75.7 million people and led to 32.7 million deaths. Much progress has been made in developing effective treatments and improving prevention options, but the challenge of developing a safe and globally effective vaccine persists. HIV incidence has remained unchanged for over 10 years, disproportionally affecting populations in sub-Saharan Africa, with UNAIDS targets far from being reached.
Meanwhile, tuberculosis (TB) remains the leading cause of death from an infectious disease, with Africa accounting for nearly 70% of TB and 27% of TB cases among people living with HIV globally. Poor diagnostics and linkage to care, in conjunction with multidrug-resistant TB, make TB a public health crisis and health security threat.
For HIV and TB, the need for universally effective vaccines has never been more urgent as public health systems struggle with the growing cost of these epidemics and threats of new pandemics, such as COVID-19, affecting prevention and treatment. While the HIV vaccine field is still exploring multiple strategies, the TB vaccine field has found a new hope with BCG and M72/ASO1E.
Although the two epidemics affect overlapping populations and their vaccine R&D faces similar struggles, the two fields seldom interact on solving common challenges. Conversely, the SARS-Co-V2 pandemic is benefiting from decades of HIV and TB vaccine R&D with many HIV stakeholders having pivoted to COVID-19.
Co-sponsored by the Global HIV Vaccine Enterprise and the TB Vaccine Initiative (TBVI), this satellite will examine lessons learned from each R&D journey and look to a future in which integrated research supports product development. It will explore the role of the industry, how to develop mutually beneficial academic-industry relationships, and funding structures and mechanisms that create a sustainable R&D environment.

SA03.01 Where and how can we work together to address shared issues and hasten product development?
Mary MAROVICH, Division of AIDS at the National Institute of Allergy and Infectious Diseases, United States
Bart Haynes, Duke University, United States
Mark HATHERILL, South African Tuberculosis Vaccine Initiative, South Africa
Alex SCHMIDT, Bill & Melinda Gates Medical Research Institute, United States
Sanjay PHOGAT, GSK, Italy
Georgia TOMARAS, Duke University, United States
SA03.02 Is an integrated approach possible for a long-term effort?
Carl DIEFFENBACH, National Institutes of Health, Division of AIDS, United States
Nina RUSSELL, Bill & Melinda Gates Foundation, United States
Michael MAKANGA, EDCTP, Netherlands
Frank COBELENS, AIGHD, Netherlands
Maria Pau, Janssen Pharmaceutical Companies of Johnson & Johnson., Netherlands
Yazdan YAZDANPANAH, ANRS | Maladies infectieuses émergentes., France
SA03.03 Introductory Remarks
In-Kyu YOON, CEPI, United States